Opioid tolerance in methadone maintenance treatment: comparison of methadone and levomethadone in long-term treatment

Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353(9148):221–6. doi: 10.1016/S0140-6736(98)05356-2 .

Holland R, Maskrey V, Swift L, Notley C, Robinson A, Nagar J et al. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial. Addiction. 2013. doi: 10.1111/add.12439 .

Wang PW, Lin HC, Yen CN, Yeh YC, Hsu CY, Chung KS, et al. Comparison of outcomes after 3-month methadone maintenance treatment between heroin users with and without HIV infection: a 3-month follow-up study. Harm Reduction J. 2015;12:13. doi: 10.1186/s12954-015-0047-0 .

Wang K, Fu H, Longfield K, Modi S, Mundy G, Firestone R. Do community-based strategies reduce HIV risk among people who inject drugs in China? A quasi-experimental study in Yunnan and Guangxi provinces. Harm Reduction J. 2014;11:15. doi: 10.1186/1477-7517-11-15 .

Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29(3):214–26.

Ward J, Darke S, Hall W, Mattick R. Methadone maintenance and the human immunodeficiency virus: current issues in treatment and research. Br J Addict. 1992;87(3):447–53.

Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177–96. doi: 10.3109/10826089609045806 .

Wilson P, Watson R, Ralston GE. Methadone maintenance in general practice: patients, workload, and outcomes. BMJ. 1994;309(6955):641–4.

Kwan TH, Wong NS, Lee SS. Participation dynamics of a cohort of drug users in a low-threshold methadone treatment programme. Harm Reduction J. 2015;12:30. doi: 10.1186/s12954-015-0072-z .

Coid J, Carvell A, Kittler Z, Healey A, Henderson J. Opiates, criminal behaviour, and methadone treatment. 2000.

Gossop M, Mardsen J, Stewart D. NTORS after five years: the National Treatment Outcome Research Study; changes in substance use, health and criminal behaviour during the five years after intake. London: National Addiction Centre; 2001.

Havinga P, van der Velden C, de Gee A, van der Poel A. Differences in sociodemographic, drug use and health characteristics between never, former and current injecting, problematic hard-drug users in the Netherlands. Harm Reduction J. 2014;11:6. doi: 10.1186/1477-7517-11-6 .

Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA. 1965;193:646–50.

Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade—a medical technique for stopping heroin use by addicts. Trans Assoc Am Phys. 1966;79:122–36.

Dole VP, Joseph H. Long-term outcome of patients treated with methadone maintenance. Ann N Y Acad Sci. 1978;311:181–9.

Dole VP, Joseph H. Methadone maintenance: outcome after termination. N Y State J Med. 1977;77(9):1409–12.

Inturrisi CE. Pharmacology of methadone and its isomers. Minerva Anestesiol. 2005;71(7–8):435–7.

Trafton JA, Ramani A. Methadone: a new old drug with promises and pitfalls. Curr Pain Headache Rep. 2009;13(1):24–30.

Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004;19(8):565–76. doi: 10.1002/hup.630 .

Freye E, Latasch L. Development of opioid tolerance—molecular mechanisms and clinical consequences. AINSAnasthesiol Intensivmed Notfallmed Schmerzther. 2003;38(1):14–26. doi: 10.1055/s-2003-36558 .

Koch T, Hollt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther. 2008;117(2):199–206. doi: 10.1016/j.pharmthera.2007.10.003 .

Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013;65(1):223–54. doi: 10.1124/pr.112.005942 .

Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, Williams JT. Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol. 2008;74(4):972–9. doi: 10.1124/mol.108.048512 .

Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12(3):679–84.

Morgan MM, Christie MJ. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol. 2011;164(4):1322–34. doi: 10.1111/j.1476-5381.2011.01335.x .

Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289(2):1048–53.

Holtman Jr JR, Wala EP. Characterization of the antinociceptive and pronociceptive effects of methadone in rats. Anesthesiology. 2007;106(3):563–71.

Bald LK, Bermpohl F, Heinz A, Gallinat J, Gutwinski S. Heroin or conventional opioid maintenance? The patients’ perspective. J Addict Med. 2013. doi: 10.1097/ADM.0b013e3182a11ad0 .

Gutwinski S, Bald LK, Heinz A, Muller CA, Schmidt AK, Wiers C, et al. Take home maintenance medication in opiate dependence. Deutsches Arzteblatt Int. 2013;110(23–24):405–12. doi: 10.3238/arztebl.2013.0405 .

Gutwinski S, Bald LK, Gallinat J, Heinz A, Bermpohl F. Why do patients stay in opioid maintenance treatment? Subst Use Misuse. 2013. doi: 10.3109/10826084.2013.863344 .

Schoofs N, Riemer T, Bald LK, Heinz A, Gallinat J, Bermpohl F et al. Methadone and levomethadone—dosage and side effects.. Psychiatrische Praxis. 2013. doi: 10.1055/s-0033-1349627 .

Bakker A, Fazey C. Methadone tolerance testing in drug misusers. BMJ. 2006;333(7577):1056–9. doi: 10.1136/bmj.39016.471840.68 .

Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane database Syst Rev. 2003;3:CD002208. doi: 10.1002/14651858.CD002208 .

Iwersen-Bergmann S, Jungen H, Andresen-Streichert H, Muller A, Elakkary S, Puschel K, et al. Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012. Int J Legal Med. 2014;128(5):751–64. doi: 10.1007/s00414-014-1017-x .

Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341:c3172. doi: 10.1136/bmj.c3172 .

Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abus Treat. 2005;28(4):321–9. doi: 10.1016/j.jsat.2005.02.007 .

Milby JB. Methadone maintenance to abstinence. How many make it? J Nerv Ment Dis. 1988;176(7):409–22.

Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. 2001;68(1):62–74.